PMID- 19843279
OWN - NLM
STAT- MEDLINE
DCOM- 20100805
LR  - 20130524
IS  - 1399-0039 (Electronic)
IS  - 0001-2815 (Linking)
VI  - 75
IP  - 1
DP  - 2010 Jan
TI  - Successful implementation of a national HLA-B*5701 genetic testing service in 
      Canada.
PG  - 12-8
LID - 10.1111/j.1399-0039.2009.01383.x [doi]
AB  - Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI) that is used in 
      combination antiretroviral therapy in HIV-infected patients. It is currently 
      recommended as a preferred or an alternative NRTI in antiretroviral-naive 
      patients. The major toxicity of abacavir is a hypersensitivity reaction (HSR), 
      which occurs in approximately 5% of treated patients. There is a strong 
      association between the human leukocyte antigen (HLA)-B*5701 allele and abacavir 
      HSR, which has allowed for rapid acceptance of genetic screening for HLA-B*5701 
      in clinical use. Canadian clinicians working in hospital centers with HLA typing 
      capacity opted to launch a pilot project in 2006 to offer the screening test as 
      standard of care to HIV-infected patients. Currently, more than 11,000 HLA-B*5701 
      tests have been performed, among which 6.3% are positive. Continued efforts have 
      been made to ensure that testing is available to all HIV-infected patients to 
      widen the patients' therapeutic options. HLA-B*5701 screening shows clinical use 
      and preliminary data suggest cost-effectiveness.
FAU - Lalonde, R G
AU  - Lalonde RG
AD  - Immunodeficiency Service, Montreal Chest Institute, McGill University Health 
      Centre, Montreal, Quebec, Canada. richard.lalonde@muhc.mcgill.ca
FAU - Thomas, R
AU  - Thomas R
FAU - Rachlis, A
AU  - Rachlis A
FAU - Gill, M J
AU  - Gill MJ
FAU - Roger, M
AU  - Roger M
FAU - Angel, J B
AU  - Angel JB
FAU - Smith, G
AU  - Smith G
FAU - Higgins, N
AU  - Higgins N
FAU - Trottier, B
AU  - Trottier B
LA  - eng
PT  - Journal Article
DEP - 20091015
PL  - England
TA  - Tissue Antigens
JT  - Tissue antigens
JID - 0331072
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Dideoxynucleosides)
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-B*57:01 antigen)
RN  - 0 (Reverse Transcriptase Inhibitors)
RN  - WR2TIP26VS (abacavir)
SB  - IM
MH  - Alleles
MH  - Anti-HIV Agents/*adverse effects/therapeutic use
MH  - Canada
MH  - Cost-Benefit Analysis
MH  - Dideoxynucleosides/*adverse effects/therapeutic use
MH  - Drug Hypersensitivity/*genetics/immunology
MH  - Genetic Testing/economics
MH  - HIV Infections/drug therapy/economics/*genetics/immunology
MH  - HLA-B Antigens/*genetics/immunology
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Reverse Transcriptase Inhibitors/adverse effects/therapeutic use
EDAT- 2009/10/22 06:00
MHDA- 2010/08/06 06:00
CRDT- 2009/10/22 06:00
PHST- 2009/10/22 06:00 [entrez]
PHST- 2009/10/22 06:00 [pubmed]
PHST- 2010/08/06 06:00 [medline]
AID - TAN1383 [pii]
AID - 10.1111/j.1399-0039.2009.01383.x [doi]
PST - ppublish
SO  - Tissue Antigens. 2010 Jan;75(1):12-8. doi: 10.1111/j.1399-0039.2009.01383.x. Epub 
      2009 Oct 15.